Cardiovascular system

One Drop Receives CE Mark, Launches Data-Driven Insights For People Managing High Blood Pressure

Retrieved on:

Wednesday, May 26, 2021

Branches of biology, Cardiovascular system, Circulatory system, Hypertension, Cardiovascular diseases, Blood pressure, Cardiovascular physiology, Pressure, Blood, Cardiovascular disease, Hypertensive crisis, Stroke

As part of the One Drop Digital Membership , consumer and employer members worldwide can now receive in-app messages with blood pressure trends, behavioral reinforcements, and alerts for hypertensive crises.

Key Points:

As part of the One Drop Digital Membership , consumer and employer members worldwide can now receive in-app messages with blood pressure trends, behavioral reinforcements, and alerts for hypertensive crises.
ONE DROP RECEIVES CE MARK, LAUNCHES DATA-DRIVEN INSIGHTS FOR PEOPLE MANAGING HIGH BLOOD PRESSURE
Often referred to as the "silent killer," high blood pressure affects one in three American adults and two-thirds of American adults living with diabetes [ 1 ].
Left untreated, high blood pressure can lead to heart disease, heart failure, and stroke [ 2 ], making early detection and daily blood pressure management critical for cardiometabolic health.
"As with most chronic conditions, blood pressure management requires deliberate action each day, but progress occurs over time.

Global Acute Myocardial Infarction Markets, Epidemiology and Patient Flow Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on:

Monday, May 24, 2021

Health, Cardiology, Circulatory system, Cardiovascular system, Medicine, Medical emergencies, Aging-associated diseases, Acute pain, Myocardial infarction, Acute, TIMI, Acute coronary syndrome

The "Global Acute Myocardial Infarction Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Global Acute Myocardial Infarction Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
Global Acute Myocardial Infarction Epidemiology and Patient Flow Analysis - 2021, provides Acute Myocardial Infarction epidemiology, demographics, and patient flow.
The research provides population data to characterize Acute Myocardial Infarction patients, history of the disease at the population level (Acute Myocardial Infarction prevalence, Acute Myocardial Infarction incidence) and at the clinical level (from diagnosis to treated patients).
Acute Myocardial Infarction patient flow: Acute Myocardial Infarction prevalence, diagnosed, and drug-treated patients
Demographics: Acute Myocardial Infarction patients by age group, gender
The data from this research will help executives:
Establish basis for Acute Myocardial Infarction market sizing, assessing market potential, and developing drug forecast models
Identify Acute Myocardial Infarction patients segments through age groups, gender, and disease sub-types
Evaluate Acute Myocardial Infarction market opportunities, identify target patient population
View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005606/en/

Upper East Side Cardiology Launches New Vein Institute as Extension to Personalized Patient Services

Retrieved on:

Monday, May 24, 2021

Angiology, Medical specialties, Cardiovascular system, Veins, Vascular surgery, Varicose veins

NEW YORK, May 24, 2021 /PRNewswire/ --One of New York City's leading cardiac treatment centers, Upper East Side Cardiology , led by Satjit Bhusri, MD, FACC, announced today the launch of The Vein Institute - The Premier Varicose Vein Treatment Center on the Upper East Side.

Key Points:

NEW YORK, May 24, 2021 /PRNewswire/ --One of New York City's leading cardiac treatment centers, Upper East Side Cardiology , led by Satjit Bhusri, MD, FACC, announced today the launch of The Vein Institute - The Premier Varicose Vein Treatment Center on the Upper East Side.
That's why The Vein Institute is so dedicated to creating customized treatment plans for our patients to restore both their vascular health and comfort."
The Vein Institute at Upper East Side Cardiology offers several, personalized treatment options for varicose veins, most of which are covered by insurance including:
VenaSeal an advanced technique that quickly and safely eliminates the veins using a specially formulated adhesive.
Dr. Bhusri is one of the only physicians on the Upper East Side to utilize this leading technology for the treatment of varicose veins.

Global Atherosclerosis Markets, Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com

Retrieved on:

Friday, May 21, 2021

Health, Cardiology, Medical specialties, Cardiovascular system, Circulatory system, Vascular diseases, Atherosclerosis

b'The "Global Atherosclerosis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Atherosclerosis Epidemiology and Patient Flow Analysis - 2021, provides Atherosclerosis epidemiology, demographics, and patient flow.

Key Points:

b'The "Global Atherosclerosis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Atherosclerosis Epidemiology and Patient Flow Analysis - 2021, provides Atherosclerosis epidemiology, demographics, and patient flow.
The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Atherosclerosis patients, history of the disease at the population level (Atherosclerosis prevalence, Atherosclerosis incidence) and at the clinical level (from diagnosis to treated patients).
It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Atherosclerosis patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Atherosclerosis market sizing, assessing market potential, and developing drug forecast models\nIdentify Atherosclerosis patients segments through age groups, gender, and disease sub-types\n'

Acceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference

Retrieved on:

Wednesday, May 19, 2021

We look forward to collecting additional, potentially confirmatory data through this ongoing open-label extension study and in the next phase of clinical development.\xe2\x80\x9d\nSotatercept was generally well tolerated in the trial.

Key Points:

We look forward to collecting additional, potentially confirmatory data through this ongoing open-label extension study and in the next phase of clinical development.\xe2\x80\x9d\nSotatercept was generally well tolerated in the trial.
The primary endpoint of the trial was the change from baseline in pulmonary vascular resistance (PVR) over a 24-week treatment period.
PVR, as measured by right heart catheterization, is the resistance that the heart must overcome to pump blood through the pulmonary circulatory system.
In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial.

Outlook on the Pulmonary Hypertension Global Market to 2035 - ResearchAndMarkets.com

Retrieved on:

Tuesday, May 18, 2021

Health, General Health, Hypertension, Pulmonary hypertension, Cardiovascular system, Circulatory system, Anatomy, Pulmonary Hypertension Association, Chronic thromboembolic pulmonary hypertension

b'The "Global Pulmonary Hypertension Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis report provides Pulmonary Hypertension epidemiology, demographics, and patient flow.

Key Points:

b'The "Global Pulmonary Hypertension Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis report provides Pulmonary Hypertension epidemiology, demographics, and patient flow.
The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Pulmonary Hypertension patients, history of the disease at the population level (Pulmonary Hypertension prevalence, Pulmonary Hypertension incidence) and at the clinical level (from diagnosis to treated patients).
It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Pulmonary Hypertension patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Pulmonary Hypertension market sizing, assessing market potential, and developing drug forecast models\nIdentify Pulmonary Hypertension patients segments through age groups, gender, and disease sub-types\nEvaluate Pulmonary Hypertension market opportunities, identify target patient population\n1.
Global Pulmonary Hypertension Patient Flow, 2020\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210518005833/en/\n'

Global Atrial Fibrillation Epidemiology and Patient Flow - 2021 Market Report - ResearchAndMarkets.com

Retrieved on:

Tuesday, May 18, 2021

Health, Cardiology, Cardiac arrhythmia, Circulatory system, Atrial fibrillation, Cardiovascular system, Cardiology, Atrium, Atrial flutter, Michel Haïssaguerre

b'The "Global Atrial Fibrillation Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis research report provides Atrial Fibrillation epidemiology, demographics, and patient flow.

Key Points:

b'The "Global Atrial Fibrillation Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis research report provides Atrial Fibrillation epidemiology, demographics, and patient flow.
The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Atrial Fibrillation patients, history of the disease at the population level (Atrial Fibrillation prevalence, Atrial Fibrillation incidence) and at the clinical level (from diagnosis to treated patients).
It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Atrial Fibrillation patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Atrial Fibrillation market sizing, assessing market potential, and developing drug forecast models\nIdentify Atrial Fibrillation patients segments through age groups, gender, and disease sub-types\nEvaluate Atrial Fibrillation market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210518005832/en/\n'

New 10-Year Data Demonstrate Superiority of the HeartFlow Analysis in Predicting Long-Term Outcomes in Patients With Coronary Artery Disease

Retrieved on:

Tuesday, May 18, 2021

Data management, Health, Technology, Hospitals, Software, General Health, Cardiology, Circulatory system, Heart diseases, Cardiovascular system, Anatomy, Coronary arteries, Coronary artery disease, Coronary, the HeartFlow FFRct Analysis, HeartFlow, Inc., THE HEARTFLOW FFRCT ANALYSIS, HEARTFLOW, INC.

The 10-year results from the DISCOVER-FLOW trial were presented as a late-breaking trial during the virtual EuroPCR conference.\n\xe2\x80\x9cWhen diagnosing and managing patients with coronary artery disease, physicians want to understand the impact of treatment.

Key Points:

The 10-year results from the DISCOVER-FLOW trial were presented as a late-breaking trial during the virtual EuroPCR conference.\n\xe2\x80\x9cWhen diagnosing and managing patients with coronary artery disease, physicians want to understand the impact of treatment.
The HeartFlow Analysis then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and provides FFRct values along the coronary arteries.
Our non-invasive HeartFlow FFRct Analysis leverages artificial intelligence to create a personalized 3D model of the heart.
The HeartFlow FFRct Analysis is commercially available in the United States, Canada, Europe and Japan.

Imbria Pharmaceuticals Presents Phase 1 and Preclinical Data of IMB-1018972 (IMB-101), an Investigational Cardiac Mitotrope, at the American College of Cardiology 70th Annual Scientific Session & Expo

Retrieved on:

Monday, May 17, 2021

In a separate preclinical study, IMB-101 improved cardiac remodeling and function in a clinically relevant disease model of heart failure (murine permanent coronary artery ligation).

Key Points:

In a separate preclinical study, IMB-101 improved cardiac remodeling and function in a clinically relevant disease model of heart failure (murine permanent coronary artery ligation).
The two studies were featured in presentations at The American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21).\n\xe2\x80\x9cOur Phase 1 healthy volunteer study data add to the growing evidence that oral administration of IMB-101 is a well-tolerated metabolic agent,\xe2\x80\x9d said Anne Prener, M.D., Ph.D., President and CEO of Imbria Pharmaceuticals.
\xe2\x80\x9cIn our preclinical study, we found IMB-101 administered in a murine surgical model of post-myocardial infarction heart failure mice progressively improved left ventricular systolic function while reducing myocardial fibrosis.
The MAD part (n=12/cohort) used 50 and 150 mg IMB-101 or placebo twice per day for 14 days.

Simulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet’s Potential to Lower Absolute Cardiovascular Event Risk Presented at ACC.21

Retrieved on:

Saturday, May 15, 2021

Medical specialties, Circulatory system, Cardiovascular system, Cardiology, Lipoproteins, Bempedoic acid, Statin, Low-density lipoprotein, Cardiovascular disease, Lipid-lowering agent

Using observed changes in LDL-C at week 12, researchers applied the CTT coefficient to calculate an estimated 10-year cardiovascular event relative risk reduction rate.

Key Points:

Using observed changes in LDL-C at week 12, researchers applied the CTT coefficient to calculate an estimated 10-year cardiovascular event relative risk reduction rate.
In these studies, NEXLETOL provided an average of 18% placebo-corrected LDL-C lowering at week 12 when used with moderate or high-intensity statins.
The effect of NEXLETOL on cardiovascular morbidity and mortality has not been determined.\nElevations in serum uric acid have occurred.
\xe2\x80\x9cRationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance.\xe2\x80\x9d American Heart Journal.